Nektar Therapeutics (LON:0UNL)

Market Cap	1.06B +751.0%
Revenue (ttm)	46.57M -32.8%
Net Income	-89.82M
EPS	-5.88
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,424
Average Volume	7,498
Open	66.00
Previous Close	65.81
Day's Range	60.90 - 69.37
52-Week Range	21.09 - 68.54
Beta	1.34
RSI	77.05
Earnings Date	Feb 26, 2026

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution pro...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1990
• Employees: 61
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0UNL

Financial Performance

In 2024, Nektar Therapeutics's revenue was $98.43 million, an increase of 9.22% compared to the previous year's $90.12 million. Losses were -$118.96 million, -56.91% less than in 2023.

Financial numbers in USD